Full-Service FDA Premarket Cybersecurity for Diabetes & CGM
End-to-end FDA premarket cybersecurity for CGMs, pumps, and AID systems - SPDF, BLE/cloud threat model, dose-safety risk controls, eSTAR-ready.
Last reviewed March 2026 · Reviewed against the FDA Feb 3, 2026 final premarket cybersecurity guidance.
Premarket cybersecurity for diabetes devices is uniquely shaped by two things: the dose-delivery actuator (turning a cyber finding into a direct patient-harm scenario) and the consumer-grade BLE pairing model (turning every device into a wireless-attack target reviewers know how to ask about). Our full-service premarket package for this segment delivers the SPDF, threat model, SBOM, pen testing, security architecture views, and labeling as a single coordinated package, all built around the dose-safety risk controls that ISO 14971 and IEC 62304 Class C demand for this segment.
We build the threat model around four data flows: sensor-to-mobile, mobile-to-pump, pump-to-cloud, and any device-to-device communication in AID systems. We map every identified threat to a hazard in your ISO 14971 file with explicit dose-safety impact. The SBOM covers the embedded firmware, the mobile app dependencies, and the cloud follow-up backend - including the Tidepool-style data sharing layer if you have one. Pen testing exercises BLE pairing, the dose-command channel, the mobile app under instrumented runtime, and the cloud APIs for cross-account leakage (the published incident pattern in this space). The eSTAR cybersecurity sections are written so the reviewer can check off each 524B requirement without bouncing between documents. We've delivered this for AID systems through 510(k), De Novo, and PMA.
Layers we exercise in this engagement
The diabetes / cgm system, from the outermost cloud and clinician surfaces down to the device itself. Highlighted layers are exercised by this full-service fda premarket cybersecurity.
- 01Clinician dashboard
- 02Cloud APIs Tested
- 03Mobile companion app Tested
- 04BLE pairing Tested
- 05Sensor / transmitter Tested
- 06Insulin pump (closed-loop) Tested
Layers shown outermost (top) to innermost (bottom). Dashed rows are part of the surrounding system but out of scope for this view.
Full-Service FDA Premarket Cybersecurity engagement, end to end
Four phases, fixed fee, scoped to diabetes / cgm architecture from kickoff onward.
-
01
Submission gap check
Existing artifacts mapped against Section 524B(b) and the Feb 2026 guidance; gaps flagged in one document.
-
02
Artifact production
Threat model, SBOM + VEX, SPDF, architecture views, cybersecurity risk assessment, and labeling produced or upgraded as needed.
-
03
Pen test + evidence
Independent pen test executed and findings closed before lock so the report ships clean inside the submission.
-
04
eSTAR-ready handoff
Every artifact delivered in the exact attachment format reviewers expect; we stay on call through the review cycle.
What we see in Diabetes / CGM full-service fda premarket cybersecurity
The patterns we hit in this segment, this service, again and again.
-
BLE pairing method not justified in threat model
Just-Works pairing chosen for UX reasons, justification not on file. Reviewers ask why; package without rationale gets a deficiency.
-
Dose-safety risk controls not cyber-traced
Hazard analysis lists dose errors; threat model lists cyber threats; the two never reference each other. Reviewer flags it.
-
Mobile app deps absent from SBOM
Embedded firmware SBOM only. Mobile-app and cloud-side SBOMs not included; reviewer requests both.
-
Closed-loop control integrity not architecturally documented
AID closed-loop control flow not in security architecture view. Reviewer requests 'global system view' that includes it.
"Blue Goat Cyber helped us navigate our first end-to-end cybersecurity testing for our wearable medical device. Their communication was excellent, their timeline exceeded expectations, and their report helped us achieve FDA clearance without any additional questions. It was a truly seamless experience."
Standard Full-Service FDA Premarket Cybersecurity deliverables
The same deliverables the parent Full-Service FDA Premarket Cybersecurity service ships with - tuned to your diabetes / cgm architecture.
- Secure Product Development Framework (SPDF)
- SBOM generation and vulnerability triage
- Threat modeling aligned to ANSI/AAMI SW96 + ISO 14971
- eSTAR-ready cybersecurity documentation
What lands in your eSTAR submission
Reviewer-format documents ready to drop straight into the cybersecurity attachments of your submission - no reformatting on your side.
- Secure Product Development Framework (SPDF)
- SBOM generation and vulnerability triage
- Threat modeling aligned to ANSI/AAMI SW96 + ISO 14971
- eSTAR-ready cybersecurity documentation
Standards that apply
The Diabetes / CGM baseline, plus the call-outs that matter for full-service fda premarket cybersecurity in this segment.
Segment-specific call-outs
IEC 62304 Class C + ISO 14971 dose-safety controls
Every cyber finding on the dose path is a Class C software risk control. Premarket package must reflect that linkage explicitly.
FDA 2026 final premarket guidance
BLE-paired devices are the canonical example reviewers cite - pairing method choice and threat-model coverage are explicit deliverables.
What's not in scope
We scope tightly on purpose. These items are either out-of-scope by design or belong in a separate engagement - we'll tell you up front, not after kickoff.
- Quality system buildout (ISO 13485 / QMSR) - separate engagement
- Clinical or biocompatibility sections of the submission
- Regulatory filing on your behalf as agent of record
Full-Service FDA Premarket Cybersecurity for Diabetes / CGM - FAQs
The questions buyers in this segment actually ask before scoping a full-service fda premarket cybersecurity engagement.
Go deeper on Diabetes / CGM and premarket
A practical, ungated buyer's guide for medical device manufacturers evaluating cybersecurity partners, what goes wrong, why it costs you, and what to demand from your next engagement. Aligned to the FDA February 2026 premarket guidance.
A practical, ungated guide to the threat modeling gaps that trigger FDA cybersecurity questions in 510(k), De Novo, and PMA submissions - and exactly how to close them before reviewers find them.
The most common cybersecurity deficiencies in 510(k), De Novo, and PMA submissions, what triggers each one and how to fix it before you file. Aligned to the FDA February 2026 final guidance and Section 524B.
What happens if you fail an FDA cybersecurity inspection: the 483-to-consent-decree enforcement ladder and the commercial fallout for device makers.
How to document update cadence for an FDA 524B submission: the regular cycle and the out-of-cycle expedited path reviewers expect under 524B(b)(2)(B).
FDA Section 524B applies to any new premarket submission for a cyber device, including legacy platforms. What attaches, what postmarket rules cover the rest.
Other engagements for Diabetes / CGM
Teams in this segment commonly bundle these alongside full-service fda premarket cybersecurity.
Keep going
Scope a Full-Service FDA Premarket Cybersecurity engagement for your diabetes / cgm program.
A 30-minute call with a senior engineer who has done this in diabetes / cgm before - not a sales rep.